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The complex genetics of human complement C4 with unusually frequent variations in the size and number of C4A
and C4B, as well as their neighboring genes, in the major histocompatibility complex has been a hurdle for accurate
epidemiological studies of diseases associated with C4. A comprehensive series of novel or improved techniques
has been developed to determine the total gene number of C4 and the relative dosages of C4A and C4B in a diploid
genome. These techniques include (1) definitive genomic restriction-fragment–length polymorphisms (RFLPs) based
on the discrete duplication patterns of the RCCX (RP-C4-CYP21-TNX) modules and on the specific nucleotide
changes for C4A and C4B isotypes; (2) module-specific PCR to give information on the total number of C4 genes
by comparing the relative quantities of RP1- or TNXB-specific fragments with TNXA-RP2 fragments; (3) labeled-
primer single-cycle DNA polymerization procedure of amplified C4d genomic DNA for diagnostic RFLP analysis
of C4A and C4B; and (4) a highly reproducible long-range–mapping method that employs PmeI-digested genomic
DNA for pulsed-field gel electrophoresis, to yield precise information on the number of long and short C4 genes
in a haplotype. Applications of these vigorously tested techniques may clarify the roles that human C4A and C4B
gene-dosage variations play in infectious and autoimmune diseases.
Introduction
Complement component C4 is a pivotal component
in the activation cascades of complement pathways.
It is a subunit of the C3 and C5 convertases for the
classical and lectin pathways that lead to the assembly
of membrane-attack complex on targets and the gen-
eration of potent anaphylatoxins C3a and C5a. The
binding of activated C4 to targets also helps the sol-
ubilization of immune aggregates, opsonizes targets
for phagocytosis by macrophages, and promotes the
immunoadherence of immune complexes to erythro-
cytes and the subsequent clearance in the liver (for
review, see Porter 1983; Blanchong et al. 2001; Jack
et al. 2001; Kohl 2001).
Human complement C4 illustrates one of the most
unusual phenomena in genetic diversity. The frequent
germline variation in the number and size of C4 genes
among different individuals is extraordinary. The copy
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number of C4 genes in a diploid human genome (i.e.,
the gene dosage) predominantly varies from two to six
in the white population (O’Neill et al. 1978; Awdeh
et al. 1979; Olaisen et al. 1980; Carroll et al. 1985;
Schneider et al. 1986; Yang et al. 1999; Blanchong et
al. 2000). Each of these genes encodes a C4A (MIM
120810) or C4B (MIM 120820) protein. Catalyzed by
the isotypic residue His-1106, the activated C4B binds
to a target rapidly but has a short half-life (!1 s)
against hydrolysis. On the contrary, the reaction rate
of activated C4A is 10 times slower than that of C4B,
and it forms amide bonds with amino group–contain-
ing targets (Dodds et al. 1996). The longer half-life of
activated C4A might have evolved to facilitate the
clearance of the immune complex. In the population,
the peripheral-blood plasma C4 protein levels range
from 80 to 1,000 mg/ml (Welch et al. 1985; Uko et al.
1986). This large range of protein levels is determined
by multiple factors, including the physiological stage
of an individual, the copy number of functional C4
genes that are present in a genome (gene dosage), and,
possibly, the polymorphism in cis-acting DNA ele-
ments that may affect the C4 expression levels. Plasma
C4 is mainly secreted by the liver, but many extrahe-
patic sites—such as the thyroid gland, the adrenal
glands, the kidneys and the heart—also synthesize sig-
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nificant levels of C4, particularly in the presence of
interferon-g (Colten and Garnier 1998; Blanchong et
al. 2001).
Deficiency of C4 increases the susceptibility to or dis-
ease severity of viral and bacterial infections (Daniels
et al. 1969; Bishof et al. 1990; Wessels et al. 1995;
Jaatinen et al. 1999). C4 deficiency is also an important
risk factor for autoimmune diseases, such as systemic
lupus erythematosus (SLE [MIM 152700]) (Atkinson
and Schneider 1999; Tsokos and Kammer 2000). On
the contrary, excessive C4 or overactivation of C4 could
aggravate an inflammatory response and render an in-
dividual more vulnerable to tissue injuries. The con-
sumption of C4 leads to repressed C4 levels in the pe-
ripheral blood and the generation of activation product
C4a and inactivation product C4d. C4a and C4d are
relevant indicators of disease activity in SLE (Wild et
al. 1990; Feucht et al. 1993) and complement-mediated
tissue injuries in transplantation, graft rejection, ische-
mia-reperfusion, and myocardial infarction (Pinckard et
al. 1975; Baldwin et al. 1999; Pfeifer et al. 2000).
C4 is a constituent of the four-gene module termed the
“RCCX,” which duplicates as a discrete genetic unit in
the class III region of the major histocompatibility com-
plex (MHC) (Yu et al. 2000). The duplicated genomic
segment is either 32.7 or 26.4 kb in size and contains
the gene fragments TNXA (Gitelman et al. 1992) and
RP2 (Shen et al. 1994), a complete C4 gene with or
without an endogenous retrovirus HERV-K(C4) in intron
9 (Dangel et al. 1994; Schneider et al. 2001), and either
a nonfunctionalCYP21A or a functionalCYP21B (White
and Speiser 2000). The variation in the number of the
RCCX modules and the size of the C4 genes leads to the
presence of seven common RCCX length variants: mono-
modular L (long) and S (short); bimodular LL and LS;
and trimodular LLL, LSS, and LLS (or LSL) (Yang et al.
1999; Blanchong et al. 2000). In addition, two rare length
variants, bimodular SS and quadrimodular LLLL, have
been implicated (Collier et al. 1989; Weg-Remers et al.
1997). These length variants create 120 different hap-
lotypic combinations of RP1/RP2 (MIM 604977), C4-
L/C4-S, CYP21A/CYP21B, and TNXA/TNXB genes in
the white population (Blanchong et al. 2000). Definitive
and efficient techniques to elucidate the number of C4A
and C4B genes and polymorphism of the protein prod-
ucts are important to determine the roles that C4A and
C4B play in disease associations, in the prognosis and
therapeutic intervention of autoimmune and inflamma-
tory diseases. Here, we present comprehensive and de-
finitive approaches to determine both the number and
length variants of the RCCX modules and the dosages
of the C4A and C4B genes. We also introduce a highly
reproducible method to illustrate the remarkable RCCX
modular variations by PmeI-digested genomic DNA for
pulsed-field gel electrophoresis (PFGE).
Material and Methods
Recruitment of Human Subjects and Preparation
of Genomic DNA
Peripheral-blood samples were taken from healthy in-
dividuals and from patients with pauciarticular JRA after
informed consent was obtained, after approval by the
Columbus Children’s Hospital institutional review board.
Genomic DNA was isolated from peripheral blood by
using the Puregene DNA isolation kit (Gentra Systems).
Southern Blot Analysis
Six micrograms of genomic DNA was digested to
completion with the appropriate restriction enzymes.
Restriction enzymes included TaqI, PshAI (New England
Biolabs), and PvuII (Invitrogen). For the PshAI-PvuII
RFLP, PshAI (15 U) was used for overnight digestion at
25C, followed by an additional 6 h of 37C incubation
with PvuII (15 U). DNA fragments were resolved by
electrophoresis in 0.7% agarose gels and were processed
as described elsewhere (Blanchong et al. 2000; Yu et al.
2002).
The DNA probes used for hybridization (as illus-
trated in fig. 1) are as follows: probe A, a 600-bp
NheI-EcoRI cDNA fragment corresponding to the 3′
end of the DNA sequence present both in RP1 and
RP2; probe D, a 1.1-kb fragment corresponding to
exons 28–31 of C4; probe 22–25, an 844-bp fragment
corresponding to exons 22–25 of C4; probe E, a 757-
bp fragment corresponding to exons 4–7 of CYP21;
and probe F, a 500-bp fragment corresponding to ex-
ons 35–37 of TNXA.
Complement C4 Allotyping and Immunoblot Analysis
EDTA-blood plasma was used to test for C4 poly-
morphism after standard procedure (Awdeh and Alper
1980; Sim and Cross 1986). In brief, diluted plasma was
treated with neuraminidase (Sigma) and carboxypepti-
dase B (Sigma), was resolved by high-voltage agarose
electrophoresis (HVAGE) based on gross electric-charge
difference of plasma proteins, was immunofixed with
goat anti-human C4 serum (Incstar), was blotted and
washed to remove diffusible proteins, was dried, and
was stained with SimplyBlue Safestain (Invitrogen). Se-
rological properties of C4 proteins were studied by im-
munoblot analysis of the C4 proteins separated by
HVAGE, using anti-Ch1 and anti-Rg1 monoclonal an-
tibodies at dilutions of 1:5,000 and 1:250, respectively.
Anti-Rg1 and anti-Ch1 monoclonal antibodies were ob-
tained from the VIIth Complement Genetic Workshop
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Figure 1 Schematic diagram of the human MHC complement gene cluster (MCGC) and eight unique modular variants of the RCCX.
A, The gene organization of the MCGC and the location of the two PmeI restriction sites. A horizontal arrow represents the direction of
transcription of a gene. A vertical arrow represents the position at which probes A, D, E, or F hybridizes to the DNA. The position of probe
22–25 is not shown, but its location is three exons upstream of probe D. B, The alignment of eight unique RCCX length variants at the telomeric
end, which are grouped into either T, B, or M haplotypes. K(C4) p endogenous retrovirus HERV-K(C4); 21A p CYP21A; 21B p CYP21B;
XA p TNXA; T p trimodular; B p bimodular; M p monomodular.
(Mauff et al. 1998). With only a few exceptions, Rg1
associates with C4A, and Ch1 usually associates with
C4B (for review, see Yu et al. 2002). Immune complexes
were detected by the chemiluminescence method using
ECL Plus reagents (Amersham Life Science).
Module-Specific PCR
Primers a, b, c, and d were designed to hybridize
to specific locations within the RCCX modules. The
primer sequences are as follows: a, 5′-CAA GAG AGG
AGG CCT ATC TTA CCT GG-3′; b, 5′-GCT CAA
GCT GTG AGG AGA ACT-3′; c, 5′-TAT CAC AGG
CTC TGG CCC CA-3′; and d, 5′-TTC GTG GTC
CAG TAC AGG GA-3′. The reaction mixture was pre-
pared as per instructions of the PLATINUM TaqPCRx
DNA Polymerase (GibcoBRL). A 1# PCRx Enhancer
Solution (GibcoBRL) was used. For the RP1/TNXA-
RP2 reaction, a concentration of 608 nM (200 ng)
primer a, 608 nM (200 ng) primer b, and 106 nM
(35 ng) primer c was used. For the TNXB/TNXA-RP2
reaction, a concentration of 304 nM (100 ng) primer
b, 304 nM (100 ng) primer c, and 198 nM (65 ng)
primer d was used. PCR conditions were as follows:
1 cycle at 94C for 3 min; 32 cycles at 94C for 45
s, 62C for 45 s, 72C for 1 min; and 1 cycle at 72C
for 10 min. DNA fragments were resolved by 1% aga-
rose gels. A digital image of the gel was captured, and
the intensity of each band was quantitatively analyzed
(by Nucleotech-GelExpert, version 4.0, or an equiv-
alent software).
Sequence-Specific Primer PCR (SSP-PCR)
Primers A-down and B-down specifically hybridize to
the isotypic sites of C4A and C4B, respectively. Primer
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E27.3 hybridizes to the 3′ end of exon 27 in C4. The
primer sequences are as follows: A-down, 5′-AGG ACC
CCT GTC CAG TGT TAG AC-3′; B-down, 5′-AGG
ACC TCT CTC CAG TGA TAC AT-3′; and E27.3, 5′-
CAC TCT CTG CTT CAA TGG CT-3′. The SSP-PCR
for C4A included primers A-down and E27.3, and that
for C4B utilized B-down and E27.3. One microliter di-
luted (1:20) E26.5/E29.3 PCR product was used as the
DNA template. PCR conditions were as follows: 1 cycle
at 94C for 3 min; 25 cycles at 94C for 30 s, 60C for
45 s, and 72C for 1 min; and 1 cycle at 72C for 10
min.
Labeling the 5′ End of C4 Primer E29.3
The reaction mixture included 15.2 mM primer E29.3,
kinase buffer (0.5 M Tris# Cl [pH 7.6], 0.1 M MgCl2,
50 mM dithiothreitol, and 1 mM EDTA), 1 mM sper-
midine, 100 mCi [g-32P] ATP, and 20 U T4 polynucleotide
kinase. The reaction was incubated at 37C for 1 h. The
radiolabeled primer E29.3 was purified by size-exclusion
chromatography using Sephadex G-25 columns, fol-
lowed by alcohol precipitation, and was resuspended in
TE (10 mM Tris and 1 mM EDTA; pH 7.4) in a final
concentration of 3.8 mM.
Labeled-Primer Single-Cycle Polymerization (LSP)
Unlabeled primers E26.5 and E29.3 were designed to
anneal to the 5′ end of exon 26 and the 3′ end of exon
29 in C4, respectively. The primer sequences are as fol-
lows: E26.5, 5′-GCT CAC AGC CTT TGT GTT GAA-
3′, and E29.3, 5′-TTG GGT ACT GCG GAA TCC CC-
3′. A 1# Premix G with the Failsafe PCR Enzyme Mix
(1.25 U) (Epicentre) was used. PCR conditions were as
follows: 1 cycle at 94C for 3 min; 34 cycles at 94C for
30 s, 58C for 45 s, 72C for 1 min; and 1 cycle at 72C
for 10 min. The PCR products were purified using a
Qiaquick PCR Purification Kit (Qiagen) and were re-
suspended in 50 ml of deionized water. A subsequent LSP
reaction was performed using 0.2 mM radiolabeled
primer E29.3 and the Failsafe PCR Enzyme Mix (0.625
U) with 1# Premix G. LSP conditions were as follows:
94C for 5 min, 58C for 5 min, and 72C for 10 min.
PshAI and XcmI RFLP of LSP Products
One-third of the LSP product was restriction digested
by PshAI or XcmI overnight at 25C and 37C, respec-
tively. DNA fragments were resolved by electrophoresis
using 1% agarose gel supplemented with ethidium bro-
mide. A digital image was captured, and the intensity of
each band was quantitatively analyzed. Subsequently,
the gel was processed by Southern blot technique and
was subjected to autoradiography, and the radioactivity
of each band was registered by phosphorimaging and
was quantified by Molecular Dynamics ImageQuant
Software, version 5.0.
PmeI RFLP Resolved by PFGE
DNA agarose plugs were prepared from white blood
cells subjected to proteinase K digestion at 50C. Prior
to restriction-enzyme digestion, the DNA agarose plugs
were washed with TE three times for 30-min intervals,
followed by an additional wash overnight, and were
equilibrated with restriction-enzyme buffer twice for 30
min each. Subsequently, the plugs were digested with
PmeI (20 U) for 4 h at 37C. DNA fragments were re-
solved by PFGE in 1% agarose in a Bio-Rad CHEF Map-
per XA System under the following conditions: gradient,
6 V/cm; calibration factor, 1.4; initial switch time, 6.75
s; final switch time, 21.79 s; run time, 37 h 40 min;
included angle, 120; ramp, linear. The gel was processed
by Southern blot technique, was hybridized with probe
D (fig. 1), and was subjected to autoradiography.
Results
Distinguishing and Enumerating the RCCX Modular
Variants using Genomic RFLPs
On the basis of differences in gene structures and nu-
cleotide polymorphism, a series of RFLP techniques was
designed to decipher the complexity of gene organiza-
tions within the RCCX modular structures (fig. 1). Five
individuals with characterized HLA class I and class II
alleles (fig. 2G) (Chung et al. 2002) and with total num-
ber of RCCX modules varying from two to six in each
genome were selected to illustrate the RCCX patterns
and the feasibility of the techniques. TaqI Southern blot
bears information on the dichotomous size variation of
C4 genes and the number of RCCX modules—hence,
the number of C4 genes—in a diploid genome. The spe-
cific length variants and the number of RCCX modules
are assigned on the basis of the presence and absence
and the relative band intensities in the three groups of
restriction fragments corresponding to (1) RP1-C4 (L or
S) andRP2-C4 (L or S), (2)CYP21A andCYP21B (MIM
201910), and (3) TNXA and TNXB (MIM 600985).
The assignment is substantiated by two additional RFLP
analyses: PshAI genomic Southern blot hybridized to an
RP 3′ probe, and BamHI genomic Southern blot hy-
bridized to a TNX 3′ probe. The PshAI RFLP establishes
the ratio of the number of RP1 genes to the number of
TNXA-RP2 hybrids, which are represented by the 7.3-
kb and 8.75-kb fragments, respectively (fig. 2B). Simi-
larly, the band intensities in the BamHI Southern blots
reflects the relative number of TNXB genes to that of
TNXA-RP2 hybrids, which are represented by the 6.5-
kb and 5.0-kb fragments, respectively (fig. 2C). Both the
RP-PshAI and TNX-BamHI RFLPs represent gross or-
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Figure 2 Defining the RCCX modular structure using different genomic RFLP Southern blot analyses. A, Restriction patterns of TaqI
RFLP for the five selected individuals on simultaneous hybridization of probes specific for 3′ RP, CYP21, and 3′ TNX. B, PshAI RFLP
hybridized to a 3′ RP probe. C, BamHI RFLP hybridized to a 3′ TNX probe. D, Phenotyping of C4A and C4B proteins by immunofixation
of EDTA-blood plasma resolved by HVAGE. E, Immunoblot analysis of Rg1 and Ch1 antigenic determinants in plasma C4 proteins after
HVAGE. F, Genomic Southern blot analysis of C4A and C4B genes by PshAI-RFLP (using Probe D) and by PshAI-PvuII RFLP (using probe
22–25). G, HLA class I and class II alleles of the five subjects.
ganizational differences between RP1 and RP2, and be-
tween the TNXA and TNXB genes.
The results of the RFLP analyses are shown in figure
2. In brief, C071 (lane 1) has homozygous monomodular
structures S/S with a total of two C4 genes in diploid.
C064 (lane 2) has heterozygous bimodular LS and
monomodular S structures with a total of threeC4 genes.
C027 (lane 3) has homozygous bimodular LL/LL with
four C4 genes. C007 (lane 4) has heterozygous trimodu-
lar and bimodular structures with five C4 genes. The
modular structures of C007 may be LLL/LS, LLS/LL, or
LSL/LL (which are indistinguishable without parallel
family segregation studies). C008 (lane 5) has homo-
zygous trimodular structures LLL with a total of six
C4 genes.
From figure 2, band intensities of the restriction frag-
ments for RP2 relative to those of RP1 increase with
the number of RCCX modules (fig. 2B, PshAI RFLP,
lanes 1–5). Similarly, band intensities of the restriction
fragments for TNXA relative to those of TNXB (figs.
2C, BamHI RFLP, and 2A, TaqI RFLP) and of the pseu-
dogene CYP21A relative to the functional gene CYP21B
(fig. 2A, TaqI RFLP) increase with the number of the
RCCX modules that are present in an individual.
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Figure 3 Module-specific PCR analysis, to detect the modular variation of RCCX.A, Schematic diagram illustrating the approximate locations
to which the primer sets a–c and b–d bind in the three modular haplotypes. B, Module-specific PCR for the RP1/TNXA-RP2 reaction, using primer
set a–c (lanes 1–5, top), and for the TNXB/TNXA-RP2 reaction, using primer set b–d (lanes 6–10, top). The relative band intensities obtained
from RP1 versus TNXA-RP2 or TNXB versus TNXA-RP2 were plotted in the graph and, except for lanes 1 and 6, are shown at bottom.
Phenotypic and Genotypic Characterization of C4A
and C4B
The variations of C4A and C4B proteins and genes
from the same five individuals were examined (figs.
2D–2F). The protein polymorphism of C4A and C4B
was determined by the immunofixation of EDTA plasma
and is resolved by HVAGE; the serological properties of
the C4A and C4B allotypes are characterized by im-
munoblot analyses using anti-Rg1 and anti-Ch1 mono-
clonal antibodies. The presence and relative gene dos-
ages of C4A and C4B were elucidated by PshAI genomic
RFLP. Since the larger restriction DNA fragment forC4B
(8.2 kb) can lead to relatively lower transfer efficiency
to the hybridization membrane than that of C4A (4.35
kb) in a Southern blot analysis, an improved strategy
employing PshAI-PvuII-digested genomic DNA was ap-
plied. By this approach, the isotype-specific fragments
for C4A and C4B were 1.7 kb and 2.2 kb, respectively,
which are smaller and closer in size, and the resultant
relative band intensities yielded more reliable informa-
tion on the C4A and C4B gene dosages.
Allotyping of C4 protein from C071 revealed the pres-
ence of C4B1 only (fig. 2D, lane 1). The PshAI and
PshAI-PvuII RFLPs demonstrated the presence of single
restriction fragments for C4B and the total absence of
the C4A fragments (fig. 2F), which is consistent with the
assignment of homozygous C4AQ0 C4B1. In C064, the
observed C4A3 allotype is associated with Rg1, and the
C4B1 and B2 allotypes are associated with Ch1. The
PshAI (or PshAI-PvuII) RFLP reveals a 2:1 ratio ofC4B:
C4A. C064 has heterozygous LS/S structures totaling
three C4 genes. The bimodular LS probably encodes
C4A3 and C4B2, and the monomodular S probably en-
codes C4B1. The remaining three individuals—C027,
C007, and C008—are identified as having C4A3 asso-
ciated with Rg1 and C4B1 associated with Ch1 (figs.
2D and 2E, lanes 3–5). There is a gradual increase in
the relative intensities of C4A versus C4B proteins be-
ginning from C027. A parallel observation can be made
for the relative dosages, of C4A:C4B genes, correspond-
ing to C027, C007, and C008 (fig. 2F), who show C4A:
C4B ratios of 3:1, 4:1, and 5:1, respectively. These
results are consistent with the C4 gene dosage deter-
mined by the TaqI genomic RFLPs.
Quantifying the Number of RCCX Modules or C4
Gene Dosage using Module-Specific PCR
A semiquantitative PCR method was developed to pro-
vide a rapid and independent method to evaluate the num-
ber of RCCX modules that are present in a diploid ge-
nome (which is equivalent to the C4 gene dosage). The
method is based on the unique structural features of the
RCCX modular duplication: each diploid genome has
two copies of the intact RP1 genes and two copies of the
intact TNXB genes, regardless of the number of RCCX
modules; noTNXA-RP2 hybrid is present in a monomod-
ular RCCX structure; and a copy of the TNXA-RP2 is
present in each additional duplicated RCCX module.
Therefore, the relative dosages of TNXA-RP2 and RP1
or of TNXA-RP2 and TNXB serve as a reliable marker
for the number of RCCX modules and, hence, the C4
gene dosage of an individual.
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Two sets of PCR primers are employed to amplify the
3′ ends of RP and the 3′ ends of TNX (fig. 3A). For RP,
the 5′ primer a is RP1 specific, and the 3′ primer b may
anneal to both RP1 and RP2. For TNX, the 5′ primer
d is TNXB specific, and the 3′ primer c may anneal to
both TNXA and TNXB. This PCR technique is applied
to the five selected individuals, and results are illustrated
in figure 3B. Lanes 1–5 represent the amplifications of
RP1 (product a-b, 1.2 kb) and TNXA-RP2 (product c-
b, 1.0 kb), using primer set a–c. Similarly, lanes 6–10
show results of amplifications of TNXB (product c-d,
0.8 kb) and TNXA-RP2 (product c-b, 1.0 kb), using
primer set b–d. The ratio of band intensities of the PCR
products for each lane, except for lanes 1 and 6, are
plotted in the graphs shown in figure 3B.
For C071, the presence of the solitary 1.2-kb fragment
corresponding to RP1 (fig. 3B, lane 1) and the 0.8-kb
fragment corresponding to TNXB (fig. 3B, lane 6) is
indicative of homozygous monomodular (M/M) RCCX
with a total of two C4 genes. For C064, the intensities
of the 1.2-kb RP1-specific fragment (fig. 3B, lane 2) and
of the 0.8-kb TNXB-specific fragment (fig. 3B, lane 7)
are twice those of their corresponding 1.0-kb TNXA-
RP2 fragments. In contrast, both RP1-specific (fig. 3B,
lane 5) and TNXB-specific (fig. 3B, lane 10) fragments
of C008 are half as intense as their corresponding
TNXA-RP2 fragments. In the former scenario (C064),
the ratio suggests heterozygous bimodular/monomodu-
lar (B/M) haplotypes with a total of three C4 genes,
whereas the latter (C008) indicates homozygous tri-
modular (fig. 3B, T/T) haplotypes with a total of six
C4 genes. Both RP1/TNXA-RP2 (fig. 3B, lane 3) and
TNXB/TNXA-RP2 (fig. 3B, lane 8) amplifications of
C027 demonstrate equal intensities between each of the
two fragments present, suggesting the presence of ho-
mozygous bimodular (B/B) RCCX structures with four
C4 genes. For C007, the 1.2-kb RP1-specific fragment
(fig. 3B, lane 4) and the 0.8-kb TNXB-specific fragment
(fig. 3B, lane 9) are slightly less intense than their cor-
responding 1.0-kb TNXA-RP2 fragment, by a ratio of
∼2:3, which is equivalent to heterozygous trimodular/
bimodular (T/B) RCCX structures with five C4 genes.
Similar to the TaqI RFLPs, module-specific PCR yields
relevant results on the number of RCCX modules or total
C4 gene dosage. However, it yields information on neither
the C4A and C4B isotypes nor the association between
the C4 genes and Rg1 or Ch1 antigenic determinants.
Determining the Presence and Dosages of C4A
and C4B Genes by SSP-PCR, PCR-RFLP, and LSP-RFLP
The C4A/C4B isotypic residues are encoded by exon
26, and the Rg1/Ch1 antigenic determinant is encoded
by exon 28. For the facilitation of the quantitation of
C4A and C4B genes, a general strategy was explored,
to allow efficient amplification of the C4d region by PCR
using different primer sets spanning exons 22–31. It was
found that the primer sets corresponding to the 5′ end
of exon 26 and to the 3′ end of exon 29 consistently
yield robust amplification of a 1.11-kb product that is
suitable for further characterization (figs. 4A and 4B).
SSP-PCR, to determine the presence of C4A and C4B
genes.—Two different forward primers, C4A-down and
C4B-down, and a common reverse primer E27.3 are used
in two independent PCRs, to determine the presence of
the C4A and C4B isotypic sequences, using the described
1.11-kb products from E26.5 to E29.3 as templates. The
forward primers incorporated the 5-nt changes for the
C4A and C4B in exon 26 (Entrez Nucleotide accession
numbers M59815 and AL049547). Results of the C4A-
and C4B-specific amplifications are shown in figure 4C.
Among the same five samples selected, C071 demon-
strates the absence of the 240-bp C4A-specific fragment
and the presence of the C4B-specific fragment. All others
give positive results for the presence of the C4A-specific
and C4B-specific fragments, as expected. However, this
SSP-PCR strategy can yield information only on the pres-
ence or absence of C4A and C4B genes but not on their
polygenic variations.
“Hot-stop PCR”–PshAI RFLP, to quantify the C4A
and C4B isotypes.—Theoretically, the relative dosage of
the C4A and C4B genes may be determined by the PshAI
or NlaIV cleavage of the E26.5/E29.3 genomic fragment
amplified by PCR. However, the formation of hetero-
duplexes among various C4A and C4B alleles during the
PCR process renders the direct PCR-RFLP results in-
accurate in the quantitative analysis of C4A and C4B
gene dosages. This is because the C4A/C4B heterodu-
plexes formed by PCR are refractory to restriction di-
gests that define C4A/C4B isotypes or Rg1/Ch1 antigenic
determinants. Therefore, the band intensities are skewed
towards fragments in which the diagnostic restriction
sites are absent. A recently developed hot-stop PCR tech-
nique employing a g-32P–labeled primer in the last round
of the PCR appears to be an attractive method to solve
the problems incurred by heteroduplexes (Uejima et al.
2000).
For determination of the validity of the hot-stop PCR,
the E29.3 primer was radiolabeled by T4 polynucleotide
kinase and g-32P-ATP. Ten nanograms of the purified, ra-
dioactive PCR primer was added to each reaction mixture,
and an additional cycle of DNA synthesis was performed.
The hot-stop PCR products were then subjected toPshAI-
RFLP analyses and autoradiograms obtained from semi-
dried agarose gels, or from Southern-blotted membranes.
Results from the initial experiments revealed relatively
weak signals that required 12 d for a visible image on an
x-ray film. Optimization was achieved by purifying the
PCR products with a commercial spin device and by
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Figure 4 PCR techniques to determine C4A/C4B gene dosage. A, Scheme depicting the intron/exon structure between exons 21 and 31
(middle) and the basis of definitive RFLP for C4A/C4B (top) and for Rg1/Ch1 (bottom). Exons are in solid boxes. Primers E26.5 and E29.3
are indicated as horizontal arrows. B, PCR products of E26.5/E29.3. C, SSP-PCR assays for the presence and absence of C4A and C4B genes.
D, LSP-PshAI or XcmI RFLP, to determine the C4A/C4B and C4 genes associated with Rg1 or Ch1, respectively. An asterisk indicates the
fragment for Rg1 with the labeled E29.3 primer. E, Graphic comparisons between expected results for the relative gene dosage of C4A and
C4B and results obtained from LSP-RFLPs and from ethidium bromide gels. Experiments with labeled DNA products digested with PshAI that
distinguishes C4A and C4B are shown at left, and results of labeled DNA products digested with XcmI that distinguishes C4 genes associated
with Rg1 and Ch1 are shown at right.
adding fresh DNA polymerase, deoxynucleoside tri-
phosphates, and the labeled primer, for LSP reaction.
Figure 4D shows the results of the LSP products for
RFLP analyses, using the E26.5/E29.3 PCR products from
the same five described samples as templates. From the
PshAI restriction digests, a 970-bp fragment represents
C4A, and a 1,110-bp fragment representsC4B.After elec-
trophoresis, a digital image was obtained from ethidium
bromide gel (fig. 4D, 1a and 2a), and an autoradiograph
was acquired from the primer-labeled restriction frag-
ments, after transfer to hybridization membrane by South-
ern blot technique. The radioactivity of each band was
registered by phosphorimaging and was quantified. Five
independent experiments were performed to examine the
consistency of results.
Consistent in both analyses from the ethidium bro-
mide gel and autoradiography of the digested LSP prod-
uct, the PshAI-digested product of C071 indicates the
presence of C4B genes only (fig. 4D, 1a and 1b, lane 1).
However, each of the four remaining individuals dem-
onstrated unequivalent results on the ratio of C4A and
C4B genes that are present in each sample between the
digitized data from ethidium bromide gel (apparent ra-
tio) and from the phosphorimaging data of the LSP-
PshAI products (LSP ratio).
The expected ratio of C4A:C4B for C064 is 1:2. The
apparent ratio of C4A:C4B from digitized images for
C064 was 1:( ), which deviated from the ex-4.3 0.4
pected ratio by twofold. In contrast, the LSP ratio ob-
tained by phosphorimaging data of the radioactive LSP-
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PshAI products for C064 was 1:( ), which is2.2 0.2
consistent with the expected result.
For C027, the expected ratio for C4A:C4B is 3:1.
The apparent ratio for C4A:C4B was ( ):1,1.5 0.1
which was again two times less than the expected ratio.
The LSP ratio obtained from phosphorimaging data was
( ):1, which was closer to the expected ratio.2.4 0.3
C007 has an expected ratio of 4:1 for C4A:C4B. The
apparent ratio was ( ):1, and the LSP ratio was2.0 0.2
( ):1. A C4A:C4B ratio of 5:1 is expected for3.0 0.2
C008, the apparent ratio was ( ):1, and the LSP2.5 0.4
ratio was ( ):1. It was noticed that, when the4.0 0.2
relative dosage of C4A:C4B is3:1, even the LSP-PshAI
analysis has a tendency to yield a slight underestimation.
Since none of the five selected individuals studied
above have an equal number of C4A and C4B genes,
an additional analysis was performed from an individual
with homozygous bimodular LL/LL, two C4A3 genes
and two C4B1 genes (fig. 4, lane 6). The expected C4A:
C4B ratio was 1:1. The apparent ratio of C4A:C4B
was 1:( ), which is approximately twofold in1.9 0.3
favor of C4B. In contrast, a ratio of 1:( ) was1.0 0.04
obtained from the analysis of phosphorimaging data
from LSP-PshAI, which accurately agrees with the ex-
pected result.
LSP-XcmI, to determine the association between C4
genes and sequences that encode Rg1/Ch1 antigenic
determinants.—To determine the relative dosages of
C4-Rg1 and C4-Ch1, the LSP products from E26.5/
E29.3 of the five individuals were subjected to XcmI
digestion. The DNA sequence encoding the Rg1 deter-
minant is distinguishable by XcmI, and the LSP product
associated with C4-Rg1 is thereby split into the 5′ frag-
ment with 585 bp and the 3′ fragment with 520 bp.
The product associated with C4-Ch1 remains as a sin-
gle 1,110-bp fragment. In an autoradiograph, only the
fragments that carry the radiolabeled E29.3 primers
(i.e., the full-length 1,110 bp for Ch1 and the 3′ frag-
ment of 520 bp associated with Rg1) are detectable.
As in the case for LSP-PshAI, the ratios of Rg1:Ch1
for each of the five individuals were measured through
five independent experiments, both from digital images
of ethidium bromide gels and from the respective phos-
phorimaging data of the Southern blots. The results are
shown in figure 4.
Similar to the scenario described for the LSP-PshAI,
a skewed, higher intensity for the 1,110-bp fragment for
Ch1 was observed in the ethidium bromide gels from
every sample that largely reflects the effects of hetero-
duplexes. By contrast, the Rg1:Ch1 ratios from phos-
phorimaging data of LSP-XcmI for C064, C027, C007,
and C008 are 1:( ), ( ):1, ( ):1.8 0.2 2.5 0.3 3.2 0.5
1, and ( ):1, respectively. In a parallel study3.76 0.3
on an individual with two C4A and C4B genes, the
apparent ratio of Rg1:Ch1 obtained from ethidium bro-
mide gels was 1:( ), which is in contrast to a1.9 0.3
ratio of 1:( ) from the phosphorimaging data1.0 0.1
generated by an LSP-XcmI-RFLP analysis.
Figure 4E is a graphic representation comparing the
expected results for the relative gene dosages of C4A
and C4B with results obtained from LSP-PshAI and LSP-
XcmI and with apparent results from ethidium bromide
gels. The LSP-RFLP results are closer to the expected
results. However, under conditions with greatly dispa-
rate proportions between C4A and C4B or between C4-
Rg1 and C4-Ch1, the LSP-PshAI and LSP-XcmI meth-
ods may underevaluate the genes with the higher dosage
(i.e., C4A and C4-Rg1).
A Novel Approach to Elucidate the Haplotypes
of RCCX Length Variants and C4 Gene Numbers
by PmeI PFGE
To deduce a method that allows consistent and defin-
itive haplotypic characterization of the number and size
of RCCX modules, we analyzed the MHC class III ge-
nomic DNA sequences generated in our laboratory (Yu
et al. 2000) and by the Human Genome Project (MHC
Sequencing Consortium 1999) for informative restric-
tion sites. The analysis showed the presence of unique
PmeI restriction sites at the 5′ region of the factor B gene
and at the 5′ end of the TNXB gene but showed none
in between (fig. 1). PmeI recognizes an 8-bp recognition
site, GTTTAAAC, and its cleavage is not dependent on
the unmethylation of CpG sequences. Therefore, the size
of the PmeI fragments resolved by PFGE hybridized to
a C4d probe in a Southern blot faithfully reflects the
number of the RCCX modules and the size of C4 genes
that are present in a haplotype. A monomodular struc-
ture with a short C4 gene is shown as a 107-kb PmeI
fragment and a monomodular structure with a long C4
gene, a 113-kb fragment. The sizes of PmeI fragments
for other RCCX structures are as follows: bimodular
LL, 146 kb; bimodular LS, 139 kb; trimodular LLL, 178
kb; trimodular LSS, 165 kb; and trimodular LLS or LSL,
172 kb.
Figure 5A depicts the result of RCCX patterns with
the PmeI PFGE from 10 individuals. Lanes 1, 2, 3, and
4 are from four individuals with homozygous structures
with trimodular LLL, bimodular LL, monomodular L,
and monomodular S, respectively. Lanes 5–10 are from
individuals with heterozygous RCCX structures. Among
these latter individuals (lanes 5–10), it is common for
one of their RCCX haplotypes to be the bimodular LL;
the other RCCX haplotypes among them are monomod-
ular L (lane 5), bimodular LS (lane 6), trimodular LSS
(lane 7), trimodular LLS or LSL (lane 8), trimodular LLL
(lane 9), and quadrimodular SSLL/SLSL/SLLS (lane 10).
The RCCX patterns of these 10 individuals were inde-
pendently analyzed by TaqI RFLP, and the results (data
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Figure 5 Elucidation of the number and size of RCCX modules present in MHC haplotypes by PmeI PFGE. A, Selected individuals, to
show homozygous and heterozygous haplotypes of length variants of RCCX structures. B, PmeI RCCX patterns of the five individuals with
two to six C4 genes, as characterized in figure 2.
not shown) are in good agreement with those obtained
with PmeI PFGE.
Figure 5B further illustrates the results of a PmeI-
PFGE analysis using genomic DNA from the same five
individuals characterized in the previous sections. As re-
vealed by a conventional genomic RFLP analysis, C071
has homozygous S/S structures, C064 is heterozygous
for LS/S, and C027 is homozygous for LL/LL. C007 (fig.
5B, lane 4, and fig. 5A, lane 8) has heterozygous, tri-
modular LSL (or LLS) and bimodular LL. C008 has ho-
mozygous LLL/LLL (fig. 5B, lane 5, and fig. 5A, lane 1).
Discussion
A number of diagnostic techniques have been presented,
to accurately determine the gene dosage of human com-
plement C4A and C4B and RCCX length variants. These
techniques are derived from our current knowledge of the
gene organizations and the sequence data of the HLA class
III region. For genomic RFLPs, we chose the restriction
enzymes that yield the maximum information, and we
deliberately designed length and locations of the hybrid-
ization probes so that the band intensities for each set of
restriction fragments on the autoradiographs or phos-
phorimages faithfully reflect the relative gene dosage of
the corresponding genes or gene segments. The TaqI ge-
nomic Southern blots using RP, CYP21, and TNX probes
yield information on the length variants of the RCCX
modules, on the total number of long and short C4 genes
linked to RP1 or to RP2, on the relative dosage of
CYP21B and CYP21A, and on the relative dosage of
TNXB and TNXA. Results of RP-PshAI Southern blots
further provided independent information, on the relative
dosage ofRP1 andRP2, that essentially yields the number
of RCCX modules present in the diploid genome of an
individual. A PshAI or PshAI-PvuII genomic Southern
blot hybridized with a C4d probe gives the results on the
relative dosage of the C4A and C4B genes. The latter is
designed to minimize artifacts caused by uneven transfer
of the C4B and C4A restriction fragments because of size
difference. The limitation of genomic RFLPs in the de-
termination C4A and C4B gene dosage and RCCX var-
iants is their requirement of relatively large quantities of
genomic DNA, which may pose constraints in multilocus
genetic studies.
Two PCR-based methods to determine C4A and C4B
gene dosages have been developed to facilitate geno-
typing when quantities of genetic materials are limited.
The module-specific PCR yields information on the
number of RCCX modules and, therefore, on the total
number of C4 genes that are present in a diploid ge-
nome. Because two different amplicons employ one
common primer and two specific primers, the PCR
products are a function of the RCCX module number
and also of the concentration of the available primers.
A titration using standard genomic DNA samples with
different C4 gene numbers is necessary to determine the
appropriate quantities of the specific primers, to yield
the expected results.
To further determine the relative dosages of C4A and
C4B, we subjected a C4d fragment amplified by PCR to
LSP-PshAI– and LSP-XcmI–RFLP analyses. The appli-
cation of a labeled primer for an additional cycle of DNA
synthesis circumvents the heteroduplex effect on diag-
nostic restriction analyses and allows for a more reliable
quantitation. We refined the original hot-stop PCR pro-
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tocol (Uejima et al. 2000), to increase the sensitivity of
detection by purifying the PCR products and performing
a single cycle of DNA synthesis in the presence of fresh
reagents and a labeled DNA primer prior to the diag-
nostic RFLP analysis. Our experiments showed that ap-
parent results obtained through the comparison of the
band intensities of the ethidium bromide–stained images
deviated significantly from the expected C4A and C4B
gene dosages. The C4B-specific fragments or the C4-Ch1
fragments are usually overrepresented by approximately
twofold. The results obtained by phosphorimaging
analyses of LSP-RFLP images are closer to the expected
C4A and C4B gene dosages. This method is most ac-
curate when the relative gene dosages of C4A and C4B
are within the range from 2:1 to 1:2. Extreme ratios
of C4A:C4B gene dosages (e.g., 4:1 or 5:1), however,
have tendencies of slight underestimation. A standard-
ization curve using the range of known C4A and C4B
gene dosages may be useful to correct this pitfall. Al-
ternatively, the precise C4 gene dosage can be deter-
mined by the application of PmeI PFGE.
Unlike the PCR-RFLP analysis, the module-specific
PCR described here is indifferent to artifacts of heter-
oduplexes. This is probably because the module-specific
PCR procedure does not require a restriction-enzyme di-
gest by which the heteroduplexes blemish the outcomes.
We attempted an alternative approach to the deter-
mination of the number of C4A and C4B genes by em-
ploying real-time PCR (Higuchi et al. 1993). The notion
was to generate amplicons spanning the exon 26–intron
26 region in the presence of two fluorescent probes, one
specific to C4A and the other specific to C4B, parallel to
the amplification of a single-copy gene as an internal
control. Thus, the results would yield the actualC4A and
C4B gene numbers. Although theoretically feasible, the
technique proved to be difficult and required extensive
optimization because of different efficiencies and poten-
tial cross-hybridizations of the C4A and C4B oligonu-
cleotide probes annealing to the C4 isotypic sequences.
The PmeI PFGE allows for elucidation of the number
and size of the RCCX modules or C4 genes that are
present in haplotypes, definitively and unambiguously.
The recognition and cleavage site of PmeI has no CpG
sequence that is common in most restriction enzymes
used for long-range mapping by PFGE. Therefore, the
PmeI-digested fragments are predictable, homogeneous,
and independent of the tissue origins of the genomic
DNA, and they reflect the actual size of DNA fragments
with the recognition sequences. Moreover, size ranges
of the restriction fragments allow a precise resolution
of the RCCX length variants in a PFGE gel. The vari-
ation in the C4 gene copy number had been investigated
previously by PFGE using BssHII-, SacII-, MluI-, or
PvuI-digested genomic DNA. Large restriction DNA
fragments were generated by cleavage of unmethylated
CpG islands that may be heterogeneous in nature, lead-
ing to “partially digested” DNA fragments (Dunham et
al. 1989; Zhang et al. 1990). It is expected that the
application of diagnostic techniques created in the pres-
ent study may advance our knowledge on the effects of
C4A and C4B gene dosage and RCCX modular vari-
ations on infectious and autoimmune diseases.
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